United Therapeutics (NASDAQ:UTHR) Given "Buy" Rating at HC Wainwright

United Therapeutics (NASDAQ:UTHR - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $300.00 target price on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 16.22% from the company's current price.

Several other equities analysts have also issued reports on UTHR. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. Wedbush reissued an "outperform" rating and issued a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. SVB Leerink started coverage on shares of United Therapeutics in a report on Monday, February 5th. They issued an "outperform" rating and a $330.00 price target for the company. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, April 11th. Finally, Leerink Partnrs reissued an "outperform" rating on shares of United Therapeutics in a report on Monday, February 5th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $306.00.

United Therapeutics Trading Up 1.2 %

UTHR stock traded up $2.99 during trading on Thursday, hitting $258.13. The company had a trading volume of 717,192 shares, compared to its average volume of 455,885. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $235.34 and a 200-day moving average price of $229.00. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $261.54. The stock has a market cap of $11.45 billion, a price-to-earnings ratio of 13.06 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analysts' expectations of $620.31 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business's revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.86 EPS. As a group, analysts predict that United Therapeutics will post 23.45 earnings per share for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the company's stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total value of $3,724,950.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company's stock, valued at approximately $32,282.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the business's stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total value of $3,724,950.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $32,282.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the business's stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares in the company, valued at $7,880,130.69. The disclosure for this sale can be found here. Insiders have sold a total of 138,190 shares of company stock worth $32,643,561 over the last quarter. Company insiders own 12.50% of the company's stock.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Daiwa Securities Group Inc. increased its stake in United Therapeutics by 15.2% in the 1st quarter. Daiwa Securities Group Inc. now owns 3,677 shares of the biotechnology company's stock worth $845,000 after acquiring an additional 485 shares during the last quarter. Nordea Investment Management AB increased its stake in United Therapeutics by 677.6% in the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company's stock worth $72,422,000 after acquiring an additional 262,222 shares during the last quarter. Access Investment Management LLC increased its stake in United Therapeutics by 137.2% in the 1st quarter. Access Investment Management LLC now owns 7,210 shares of the biotechnology company's stock worth $1,656,000 after acquiring an additional 4,170 shares during the last quarter. GLOBALT Investments LLC GA bought a new position in shares of United Therapeutics during the 1st quarter valued at about $207,000. Finally, Capstone Investment Advisors LLC increased its position in shares of United Therapeutics by 90.9% during the 1st quarter. Capstone Investment Advisors LLC now owns 5,062 shares of the biotechnology company's stock valued at $1,163,000 after purchasing an additional 2,410 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.